Key result
CCBE1 enhances lymphangiogenesis and angiogenesis by promoting ADAMTS3-mediated cleavage of VEGF-C.
Why the study?
The interaction between CCBE1 and the VEGF-C signaling pathway critical for lymphangiogenesis was unclear, particularly how CCBE1 influences VEGF-C activation.
Does CCBE1 transduction enhance VEGF-C-mediated lymphangiogenesis and angiogenesis in preclinical models?
Does CCBE1 transduction enhance VEGF-C-mediated lymphangiogenesis and angiogenesis in preclinical models?
CCBE1 enhances VEGF-C activation via the ADAMTS3 protease, promoting lymphangiogenesis and angiogenesis, and serving as a potential therapeutic target for lymphatic disorders.
May warrant caution before clinical translation in lymphedema; leaves open CCBE1-ADAMTS3 modulation of VEGF-C for targeted research.
BACKGROUND: Hennekam lymphangiectasia-lymphedema syndrome (Online Mendelian Inheritance in Man 235510) is a rare autosomal recessive disease, which is associated with mutations in the CCBE1 gene. Because of the striking phenotypic similarity of embryos lacking either the Ccbe1 gene or the lymphangiogenic growth factor Vegfc gene, we searched for collagen- and calcium-binding epidermal growth factor domains 1 (CCBE1) interactions with the vascular endothelial growth factor-C (VEGF-C) growth factor signaling pathway, which is critical in embryonic and adult lymphangiogenesis. METHODS AND RESULTS: By analyzing VEGF-C produced by CCBE1-transfected cells, we found that, whereas CCBE1 itself does not process VEGF-C, it promotes proteolytic cleavage of the otherwise poorly active 29/31-kDa form of VEGF-C by the A disintegrin and metalloprotease with thrombospondin motifs-3 protease, resulting in the mature 21/23-kDa form of VEGF-C, which induces increased VEGF-C receptor signaling. Adeno-associated viral vector-mediated transduction of CCBE1 into mouse skeletal muscle enhanced lymphangiogenesis and angiogenesis induced by adeno-associated viral vector-VEGF-C. CONCLUSIONS: These results identify A disintegrin and metalloprotease with thrombospondin motifs-3 as a VEGF-C-activating protease and reveal a novel type of regulation of a vascular growth factor by a protein that enhances its proteolytic cleavage and activation. The results suggest that CCBE1 is a potential therapeutic tool for the modulation of lymphangiogenesis and angiogenesis in a variety of diseases that involve the lymphatic system, such as lymphedema or lymphatic metastasis.
No takes yet. Share an insight, caveat, or question.
Jeltsch et al. (2014) studied Hennekam lymphangiectasia-lymphedema syndrome. CCBE1 was evaluated on Proteolytic cleavage of VEGF-C and enhancement of lymphangiogenesis. CCBE1 enhanced lymphangiogenesis and angiogenesis by promoting the proteolytic cleavage and activation of VEGF-C via A disintegrin and metalloprotease with thrombospondin motifs-3.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: